The themes Establishment Labs is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Graded A or B and worth $2B or more: A first, then the largest.
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
Built from Establishment Labs Holdings Inc.’s own filings with the U.S. Securities and Exchange Commission (SEC). Figures are as reported, with per-share history restated onto today’s share basis. This describes a business — it is not investment advice and not a recommendation to buy or sell anything.
ESTA · Nasdaq · Healthcare · Medical Devices
$70.88+3.3%Nov 13 close
Figures through September 30, 2026, from the 10-Q filed November 6, 2026
Company outlook: revenue of about $274M for Fiscal year 2026 — up 29.8% on a year earlier
Just reported
From Establishment Labs's results release of October 29, 2026; its quarterly report has since been filed.
Actual
$72M
+34% y/y
+6.6% q/q
Guided
—
No guide given
Actual
-$0.35
Guided
—
No guide given
Actual
-$2.6M
Guided
—
No guide given
Full year 2026
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
Grade B-
The band under the price shows the grade on each date, built only from filings that were public by then.
Showing 2 of 31 quarters of Establishment Labs Holdings Inc.’s grade history. The other 29 go back to May 2019.